{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T06:46:29Z","timestamp":1787726789013,"version":"build-2784847793"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,7,13]],"date-time":"2025-07-13T00:00:00Z","timestamp":1752364800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,7,13]],"date-time":"2025-07-13T00:00:00Z","timestamp":1752364800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s40262-025-01545-w","type":"journal-article","created":{"date-parts":[[2025,7,13]],"date-time":"2025-07-13T10:14:23Z","timestamp":1752401663000},"page":"1413-1423","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Revisiting Acyclovir Dosing for Adult Viral Encephalitis Using a Full Bayesian LeiCNS PBPK Modeling Approach"],"prefix":"10.1007","volume":"64","author":[{"given":"Ming","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martijn L.","family":"Manson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Grete","family":"M\u00e4rtson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Bodilsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth C. M.","family":"de Lange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7892-6220","authenticated-orcid":false,"given":"Tingjie","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,13]]},"reference":[{"issue":"9","key":"1545_CR1","first-page":"607","volume":"23","author":"A Mailles","year":"2017","unstructured":"Mailles A, Stahl JP, Bloch KC. Update and new insights in encephalitis. Clin Microbiol Infect Off Pub Eur Soc Clin Microbiol Infect Dis. 2017;23(9):607\u201313.","journal-title":"Clin Microbiol Infect Off Pub Eur Soc Clin Microbiol Infect Dis"},{"issue":"4","key":"1545_CR2","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.jinf.2011.11.014","volume":"64","author":"T Solomon","year":"2012","unstructured":"Solomon T, Michael BD, Smith PE, et al. Management of suspected viral encephalitis in adults\u2013Association of British Neurologists and British Infection Association National Guidelines. J Infect. 2012;64(4):347\u201373.","journal-title":"J Infect"},{"issue":"5","key":"1545_CR3","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s40263-024-01082-3","volume":"38","author":"M Sun","year":"2024","unstructured":"Sun M, Manson ML, Guo T, et al. CNS viral infections-what to consider for improving drug treatment: a plea for using mathematical modeling approaches. CNS Drugs. 2024;38(5):349\u201373.","journal-title":"CNS Drugs"},{"issue":"3","key":"1545_CR4","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.medmal.2017.01.005","volume":"47","author":"JP Stahl","year":"2017","unstructured":"Stahl JP, Azouvi P, Bruneel F, et al. Guidelines on the management of infectious encephalitis in adults. Med Mal Infect. 2017;47(3):179\u201394.","journal-title":"Med Mal Infect"},{"issue":"3","key":"1545_CR5","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1086\/589747","volume":"47","author":"AR Tunkel","year":"2008","unstructured":"Tunkel AR, Glaser CA, Bloch KC, et al. The management of encephalitis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2008;47(3):303\u201327.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"1545_CR6","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1111\/imj.12749","volume":"45","author":"PN Britton","year":"2015","unstructured":"Britton PN, Eastwood K, Paterson B, et al. Consensus guidelines for the investigation and management of encephalitis in adults and children in Australia and New Zealand. Intern Med J. 2015;45(5):563\u201376.","journal-title":"Intern Med J"},{"issue":"3","key":"1545_CR7","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1086\/341405","volume":"35","author":"F Raschilas","year":"2002","unstructured":"Raschilas F, Wolff M, Delatour F, et al. Outcome of and prognostic factors for herpes simplex encephalitis in adult patients: results of a multicenter study. Clin Infect Dis Off Pub Infect Dis Soc Am. 2002;35(3):254\u201360.","journal-title":"Clin Infect Dis Off Pub Infect Dis Soc Am"},{"issue":"3","key":"1545_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.japh.2024.02.013","volume":"64","author":"A Aboelezz","year":"2024","unstructured":"Aboelezz A, Mahmoud SH. Acyclovir dosing in herpes encephalitis: a scoping review. J Am Pharm Assoc JAPhA. 2024;64(3): 102040.","journal-title":"J Am Pharm Assoc JAPhA"},{"issue":"3","key":"1545_CR9","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1056\/NEJM198601163140303","volume":"314","author":"RJ Whitley","year":"1986","unstructured":"Whitley RJ, Alford CA, Hirsch MS, et al. Vidarabine versus acyclovir therapy in herpes simplex encephalitis. N Engl J Med. 1986;314(3):144\u20139.","journal-title":"N Engl J Med"},{"issue":"8405","key":"1545_CR10","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/S0140-6736(84)92623-0","volume":"2","author":"B Sk\u00f6ldenberg","year":"1984","unstructured":"Sk\u00f6ldenberg B, Forsgren M, Alestig K, et al. Acyclovir versus vidarabine in herpes simplex encephalitis. Randomised multicentre study in consecutive Swedish patients. Lancet. 1984;2(8405):707\u201311.","journal-title":"Lancet"},{"issue":"6","key":"1545_CR11","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1002\/cpt1979266718","volume":"26","author":"P de Miranda","year":"1979","unstructured":"de Miranda P, Whitley RJ, Blum MR, et al. Acyclovir kinetics after intravenous infusion. Clin Pharmacol Ther. 1979;26(6):718\u201328.","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"1545_CR12","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1093\/jac\/24.6.947","volume":"24","author":"J Lycke","year":"1989","unstructured":"Lycke J, Andersen O, Svennerholm B, et al. Acyclovir concentrations in serum and cerebrospinal fluid at steady state. J Antimicrob Chemother. 1989;24(6):947\u201354.","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"1545_CR13","doi-asserted-by":"publisher","first-page":"2918","DOI":"10.1128\/AAC.01138-08","volume":"53","author":"L Zeng","year":"2009","unstructured":"Zeng L, Nath CE, Blair EYL, et al. Population pharmacokinetics of acyclovir in children and young people with malignancy after administration of intravenous acyclovir or oral valacyclovir. Antimicrob Agents Chemother. 2009;53(7):2918\u201327.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"1545_CR14","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1128\/AAC.45.1.150-157.2001","volume":"45","author":"M Tod","year":"2001","unstructured":"Tod M, Lokiec F, Bidault R, et al. Pharmacokinetics of oral acyclovir in neonates and in infants: a population analysis. Antimicrob Agents Chemother. 2001;45(1):150\u20137.","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"1545_CR15","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1128\/AAC.01426-20","volume":"64","author":"S Abdalla","year":"2020","unstructured":"Abdalla S, Briand C, Oualha M, et al. Population pharmacokinetics of intravenous and oral acyclovir and oral valacyclovir in pediatric population to optimize dosing regimens. Antimicrob Agents Chemother. 2020;64(12):10\u20131128.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"1545_CR16","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1002\/psp4.12926","volume":"12","author":"A Elmokadem","year":"2023","unstructured":"Elmokadem A, Zhang Y, Knab T, et al. Bayesian PBPK modeling using R\/Stan\/Torsten and Julia\/SciML\/Turing.Jl. CPT Pharmacometrics Syst Pharmacol. 2023;12(3):300\u201310.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"10","key":"1545_CR17","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1002\/psp4.12134","volume":"5","author":"L Kuepfer","year":"2016","unstructured":"Kuepfer L, Niederalt C, Wendl T, et al. Applied concepts in PBPK modeling: how to build a PBPK\/PD model. CPT Pharmacomet Syst Pharmacol. 2016;5(10):516\u201331.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"issue":"12","key":"1545_CR18","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1080\/17460441.2017.1380623","volume":"12","author":"ECM de Lange","year":"2017","unstructured":"de Lange ECM, van den Brink W, Yamamoto Y, et al. Novel CNS drug discovery and development approach: model-based integration to predict neuro-pharmacokinetics and pharmacodynamics. Expert Opin Drug Discov. 2017;12(12):1207\u201318.","journal-title":"Expert Opin Drug Discov"},{"issue":"5","key":"1545_CR19","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s10928-021-09768-7","volume":"48","author":"MAA Saleh","year":"2021","unstructured":"Saleh MAA, Loo CF, Elassaiss-Schaap J, et al. Lumbar cerebrospinal fluid-to-brain extracellular fluid surrogacy is context-specific: insights from LeiCNS-PK3.0 simulations. J Pharmacokinet Pharmacodyn. 2021;48(5):725\u201341.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"3","key":"1545_CR20","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1128\/AAC.00729-09","volume":"54","author":"JP Smith","year":"2010","unstructured":"Smith JP, Weller S, Johnson B, et al. Pharmacokinetics of acyclovir and its metabolites in cerebrospinal fluid and systemic circulation after administration of high-dose valacyclovir in subjects with normal and impaired renal function. Antimicrob Agents Chemother. 2010;54(3):1146\u201351.","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"1545_CR21","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1128\/AAC.47.8.2438-2441.2003","volume":"47","author":"J Lycke","year":"2003","unstructured":"Lycke J, Malmestr\u00f6m C, St\u00e5hle L. Acyclovir levels in serum and cerebrospinal fluid after oral administration of valacyclovir. Antimicrob Agents Chemother. 2003;47(8):2438\u201341.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"1545_CR22","first-page":"1593","volume":"15","author":"MD Hoffman","year":"2014","unstructured":"Hoffman MD, Gelman A. The No-U-Turn sampler: adaptively setting path lengths in Hamiltonian Monte Carlo. J Mach Learn Res. 2014;15(1):1593\u2013623.","journal-title":"J Mach Learn Res"},{"issue":"2","key":"1545_CR23","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/rssa.12378","volume":"182","author":"J Gabry","year":"2019","unstructured":"Gabry J, Simpson D, Vehtari A, et al. Visualization in Bayesian workflow. J R Stat Soc Ser A Stat Soc. 2019;182(2):389\u2013402.","journal-title":"J R Stat Soc Ser A Stat Soc"},{"issue":"4","key":"1545_CR24","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1002\/cpt.2198","volume":"109","author":"CR Rayner","year":"2021","unstructured":"Rayner CR, Smith PF, Andes D, et al. Model-informed drug development for anti-infectives: state of the art and future. Clin Pharmacol Ther. 2021;109(4):867\u201391.","journal-title":"Clin Pharmacol Ther"},{"issue":"11","key":"1545_CR25","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.3390\/pharmaceutics14112311","volume":"14","author":"GF Grit","year":"2022","unstructured":"Grit GF, M\u00e4rtson A-G, Knoester M, et al. Shedding a light on acyclovir pharmacodynamics: a retrospective analysis on pharmacokinetic\/pharmacodynamic modelling of acyclovir for the treatment of varicella zoster virus infection in immunocompromised patients: a pilot study. Pharmaceutics. 2022;14(11):2311.","journal-title":"Pharmaceutics"},{"issue":"1","key":"1545_CR26","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.cld.2012.09.003","volume":"17","author":"A Chatterjee","year":"2013","unstructured":"Chatterjee A, Smith PF, Perelson AS. Hepatitis C viral kinetics: the past, present, and future. Clin Liver Dis. 2013;17(1):13\u201326.","journal-title":"Clin Liver Dis"},{"issue":"4","key":"1545_CR27","first-page":"534","volume":"31","author":"R Nau","year":"2025","unstructured":"Nau R, Seele J, Bodilsen J, et al. Optimization of antiviral dosing in Herpesviridae encephalitis: a promising approach to improve outcome? Clin Microbiol Infect Off Pub Eur Soc Clin Microbiol Infect Dis. 2025;31(4):534\u201341.","journal-title":"Clin Microbiol Infect Off Pub Eur Soc Clin Microbiol Infect Dis"},{"issue":"5","key":"1545_CR28","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1093\/jac\/dkl067","volume":"57","author":"A Helld\u00e9n","year":"2006","unstructured":"Helld\u00e9n A, Lycke J, Vander T, et al. The aciclovir metabolite CMMG is detectable in the CSF of subjects with neuropsychiatric symptoms during aciclovir and valaciclovir treatment. J Antimicrob Chemother. 2006;57(5):945\u20139.","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"1545_CR29","first-page":"1135","volume":"18","author":"A Helld\u00e9n","year":"2003","unstructured":"Helld\u00e9n A, Odar-Cederl\u00f6f I, Diener P, et al. High serum concentrations of the acyclovir main metabolite 9-carboxymethoxymethylguanine in renal failure patients with acyclovir-related neuropsychiatric side effects: an observational study. Nephrol Dial Transplant Off Pub Eur Dial Transplant Assoc Eur Ren Assoc. 2003;18(6):1135\u201341.","journal-title":"Nephrol Dial Transplant Off Pub Eur Dial Transplant Assoc Eur Ren Assoc"},{"issue":"5","key":"1545_CR30","first-page":"290","volume":"158","author":"P Gunness","year":"2011","unstructured":"Gunness P, Aleksa K, Bend J, et al. Acyclovir-induced nephrotoxicity: the role of the acyclovir aldehyde metabolite. Transl Res J Lab Clin Med. 2011;158(5):290\u2013301.","journal-title":"Transl Res J Lab Clin Med"},{"issue":"3","key":"1545_CR31","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/s42255-021-00357-z","volume":"3","author":"S Jin","year":"2021","unstructured":"Jin S, Cao Q, Yang F, et al. Brain ethanol metabolism by astrocytic ALDH2 drives the behavioural effects of ethanol intoxication. Nat Metab. 2021;3(3):337\u201351.","journal-title":"Nat Metab"},{"issue":"19","key":"1545_CR32","first-page":"5045","volume":"268","author":"SE Mart\u00ednez","year":"2001","unstructured":"Mart\u00ednez SE, Vaglenova J, Sabri\u00e0 J, et al. Distribution of alcohol dehydrogenase mRNA in the rat central nervous system. Consequences for brain ethanol and retinoid metabolism. Eur J Biochem. 2001;268(19):5045\u201356.","journal-title":"Eur J Biochem"},{"issue":"10","key":"1545_CR33","doi-asserted-by":"publisher","first-page":"3493","DOI":"10.1007\/s00467-023-05881-6","volume":"38","author":"C Collignon","year":"2023","unstructured":"Collignon C, de Marcellus C, Oualha M, et al. Pharmacokinetic profile of acyclovir in a child receiving continuous kidney replacement therapy for acute liver failure. Pediatr Nephrol. 2023;38(10):3493\u20137.","journal-title":"Pediatr Nephrol"},{"key":"1545_CR34","volume":"2024","author":"A Aboelezz","year":"2003","unstructured":"Aboelezz A, Mahmoud SH. Acyclovir dosing in herpes encephalitis: a scoping review. J Am Pharm Assoc. 2003;2024: 102040.","journal-title":"J Am Pharm Assoc"},{"issue":"7","key":"1545_CR35","doi-asserted-by":"publisher","first-page":"3624","DOI":"10.1128\/AAC.01023-10","volume":"55","author":"T Pouplin","year":"2011","unstructured":"Pouplin T, Pouplin JN, Van Toi P, et al. Valacyclovir for herpes simplex encephalitis. Antimicrob Agents Chemother. 2011;55(7):3624\u20136.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1a","key":"1545_CR36","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/0002-9343(82)90084-5","volume":"73","author":"RJ Whitley","year":"1982","unstructured":"Whitley RJ, Blum MR, Barton N, et al. Pharmacokinetics of acyclovir in humans following intravenous administration. A model for the development of parenteral antivirals. Am J Med. 1982;73(1a):165\u201371.","journal-title":"Am J Med"},{"issue":"1a","key":"1545_CR37","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/0002-9343(82)90088-2","volume":"73","author":"MR Blum","year":"1982","unstructured":"Blum MR, Liao SH, de Miranda P. Overview of acyclovir pharmacokinetic disposition in adults and children. Am J Med. 1982;73(1a):186\u201392.","journal-title":"Am J Med"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01545-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-025-01545-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01545-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T01:14:31Z","timestamp":1757466871000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-025-01545-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,13]]},"references-count":37,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["1545"],"URL":"https:\/\/doi.org\/10.1007\/s40262-025-01545-w","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,13]]},"assertion":[{"value":"27 June 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funding was received for the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors declared no competing interests for this work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Written, informed consent was obtained from all participants.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Data generated during and analyzed during the current study are not publicly available due privacy but are available on reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"The model codes that support the findings of this study are accessible upon reasonable request.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Conceptualization: E.C.M.D.L. and T.G. Data collection: M.S.\u00a0Formal analysis and investigation: M.S., M.L.M., E.C.M.D.L., and T.G. Writing, review, and editing: M.S., M.L.M., A.G.M., J.B., E.C.M.D.L. and T.G.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}